The Pathology of Melanoma

Dermatologic Clinics

Volumn 30, Issue 3, 2012, Pages 445-468

  Cockerell, Clay J ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Cutaneous melanoma; Melanoma; Pathology; Skin cancer

Indexed keywords

EOSIN; HEMATOXYLIN;

ACROLENTIGINOUS MELANOMA; ANIMAL MELANOMA; BALLOON CELL MELANOMA; CANCER CLASSIFICATION; CANCER GROWTH; CANCER MORTALITY; CANCER PROGNOSIS; CANCER STAGING; CLEAR CELL SARCOMA; CLINICAL FEATURE; COMPARATIVE GENOMIC HYBRIDIZATION; CONGENITAL NEVUS; CUTANEOUS MELANOMA; CYTOGENETICS; DERMOEPIDERMAL JUNCTION; DESMOPLASTIC MELANOMA; DIAGNOSTIC ACCURACY; DYSPLASTIC NEVUS; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLICULAR MELANOMA; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MALIGNANT BLUE NEVUS; METASTASIS POTENTIAL; METASTATIC MELANOMA; MITOSIS RATE; NEVOID MELANOMA; PRIORITY JOURNAL; REVIEW; SARCOMATOID MELANOMA; SATELLITE METASTASIS; SENTINEL LYMPH NODE BIOPSY; SKIN BIOPSY; SKIN CARCINOGENESIS; SKIN METASTASIS; SKIN ULCER; SPINDLE CELL MELANOMA; SPITZOID MELANOMA; TUMOR ASSOCIATED LEUKOCYTE; TUMOR REGRESSION; VERRUCOUS MELANOMA;

BIOPSY; CYTOGENETIC ANALYSIS; HUMANS; MELANOMA; PROGNOSIS; SKIN; SKIN NEOPLASMS; STAINING AND LABELING;

EID: 84863863281     PISSN: 07338635     EISSN: 15580520     Source Type: Journal    
DOI: 10.1016/j.det.2012.04.007     Document Type: Review

References (162)

1. Linos E., Swetter S.M., Clarke C.A., et al. Increasing burden of melanoma in the United States. J Invest Dermatol 2009, 129:1666-1674.
2. Jemal A., Tiwari R.C., Ward E., et al. Cancer statistics, 2004. CA Cancer J Clin 2004, 54:8-29.
3. Jemal A., Siegel R., Xu J., et al. Cancer statistics, 2010. CA Cancer J Clin 2010, 60:277-300.
4. Plotnick H., Rachmaninoff N., VandenBerg H.J. Polypoid melanoma: a virulent variant of nodular melanoma. Report of three cases and literature review. J Am Acad Dermatol 1990, 23:880-884.
5. Pizzichetta M.A., Talamini R., Argenziano G., et al. Amelanotic/hypomelanotic melanoma: clinical and dermoscopic features. Br J Dermatol 2004, 150:1117-1124.
6. Giuliano A.E., Cochran A.J., Morton D.L. Melanoma from unknown primary site and amelanotic melanoma. Semin Oncol 1982, 9:442-447.
7. Bono A., Maurichi A., Lualdi M., et al. Clinical and dermatoscopic diagnosis of early amelanotic melanoma. Melanoma Res 2001, 11:491-494.
8. Montgomery R.M. Differential diagnosis and treatment of warts. West Med Med J West 1967, 1:34-36.
9. Kuehnl-Petzoldt C., Berger H., Wiebelt H. Verrucous-keratotic variations of malignant melanoma: a clinicopathological study. Am J Dermatopathol 1982, 4:403-410.
10. Suster S., Ronnen M., Bubis J.J. Verrucous pseudonevoid melanoma. J Surg Oncol 1987, 36:134-137.
11. Steiner A., Konrad K., Wolff K., et al. Verrucous malignant melanoma. Arch Dermatol 1988, 124:1534-1537.
12. Blessing K., Evans A.T., al-Nafussi A. Verrucous naevoid and keratotic malignant melanoma: a clinico-pathological study of 20 cases. Histopathology 1993, 23:453-458.
13. Hantschke M., Mentzel T., Kutzner H. Follicular malignant melanoma: a variant of melanoma to be distinguished from lentigo maligna melanoma. Am J Dermatopathol 2004, 26:359-363.
14. Hu S.W., Tahan S.R., Kim C.C. Follicular malignant melanoma: a case report of a metastatic variant and review of the literature. J Am Acad Dermatol 2011, 64:1007-1010.
15. Granter S.R., McKee P.H., Busam K., et al. Melanoma associated with blue nevus and melanoma mimicking cellular blue nevus: a clinicopathologic study of 10 cases on the spectrum of so-called 'malignant blue nevus'. Am J Surg Pathol 2001, 25:316-323.
16. Ackerman A.B. Malignant melanoma: a unifying concept. Hum Pathol 1980, 11:591-595.
17. Ackerman A.B., David K.M. A unifying concept of malignant melanoma: biologic aspects. Hum Pathol 1986, 17:438-440.
18. Bono A., Bartoli C., Grassi G., et al. Small melanomas: a clinical study on 270 consecutive cases of cutaneous melanoma. Melanoma Res 1999, 9:583-586.
19. Balch C.M., Soong S.J., Cascinelli N., et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001, 19:3622-3634.
20. Leiter U., Meier F., Garbe C., et al. The natural course of cutaneous melanoma. J Surg Oncol 2004, 86:172-178.
21. Clark W.H., Elder D.E., Van Horn M., et al. A study of tumor progression: the precursor lesions of superficial spreading and nodular melanoma. Hum Pathol 1984, 15:1147-1165.
22. Clark W.H., Elder D.E., Van Horn M. The biologic forms of malignant melanoma. Hum Pathol 1986, 17:443-450.
23. Elder D.E., Guerry D.T., Van Horn M., et al. Invasive malignant melanomas lacking competence for metastasis. Am J Dermatopathol 1984, 6:55-61.
24. Herlyn M., Clark W.H., Koprowski H., et al. Biology of tumor progression in human melanocytes. Lab Invest 1987, 56:461-474.
25. Barnhill R.L., Mihm M.C. The histopathology of cutaneous malignant melanoma. Semin Diagn Pathol 1993, 10:47-75.
26. Coit D.G., Andtbacka R., Guild V., et al. Melanoma. J Natl Compr Canc Netw 2009, 7:250-275.
27. Ng P.C., Barzilai D.A., Gilliam A.C., et al. Evaluating invasive cutaneous melanoma: is the initial biopsy representative of the final depth?. J Am Acad Dermatol 2003, 48:420-424.
28. Decarlo K., Yang S., Mahalingam M., et al. Oncogenic BRAF-positive dysplastic nevi and the tumor suppressor IGFBP7-challenging the concept of dysplastic nevi as precursor lesions?. Hum Pathol 2010, 41:886-894.
29. Karimipour D.J., Schwartz J.L., King A.L., et al. Microstaging accuracy after subtotal incisional biopsy of cutaneous melanoma. J Am Acad Dermatol 2005, 52:798-802.
30. Bichakjian C.K., Halpern A.C., Swetter S.M., et al. Guidelines of care for the management of primary cutaneous melanoma. J Am Acad Dermatol 2011, 65:1032-1047.
31. Stell V.H., Norton H.J., White R.L., et al. Method of biopsy and incidence of positive margins in primary melanoma. Ann Surg Oncol 2007, 14:893-898.
32. Austin J.R., Byers R.M., Wolf P., et al. Influence of biopsy on the prognosis of cutaneous melanoma of the head and neck. Head Neck 1996, 18:107-117.
33. Ng J.C., Swain S., Kelly J.W., et al. The impact of partial biopsy on histopathologic diagnosis of cutaneous melanoma: experience of an Australian tertiary referral service. Arch Dermatol 2010, 146:234-239.
34. Pariser R.J., Divers A., Nassar A. The relationship between biopsy technique and uncertainty in the histopathologic diagnosis of melanoma. Dermatol Online J 1999, 5:4.
35. Armour K., Mann S., Lee S. Dysplastic naevi: to shave, or not to shave? A retrospective study of the use of the shave biopsy technique in the initial management of dysplastic naevi. Australas J Dermatol 2005, 46:70-75.
36. Bong J.L., Herd R.M., Hunter J.A. Incisional biopsy and melanoma prognosis. J Am Acad Dermatol 2002, 46:690-694.
37. Lederman J.S., Sober A.J. Does biopsy type influence survival in clinical stage I cutaneous melanoma?. J Am Acad Dermatol 1985, 13:983-987.
38. Lees V.C., Briggs J.C. Effect of initial biopsy procedure on prognosis in Stage 1 invasive cutaneous malignant melanoma: review of 1086 patients. Br J Surg 1991, 78:1108-1110.
39. Martin R.C., Scoggins C.R., Edwards M.J., et al. Is incisional biopsy of melanoma harmful?. Am J Surg 2005, 190:913-917.
40. Ackerman A.B. Malignant melanoma. A unifying concept. Am J Dermatopathol 1980, 2:309-313.
41. Florell S.R., Boucher K.M., Malone J.C., et al. Histopathologic recognition of involved margins of lentigo maligna excised by staged excision: an interobserver comparison study. Arch Dermatol 2003, 139:595-604.
42. Heenan P.J. Nodular melanoma is not a distinct entity. Arch Dermatol 2003, 139:387. [author reply: 388].
43. Chamberlain A.J., Fritschi L., Kelly J.W., et al. Nodular type and older age as the most significant associations of thick melanoma in Victoria, Australia. Arch Dermatol 2002, 138:609-614.
44. From L., Hanna W., Baumal R., et al. Origin of the desmoplasia in desmoplastic malignant melanoma. Hum Pathol 1983, 14:1072-1080.
45. Barnhill R.L., Gupta K. Unusual variants of malignant melanoma. Clin Dermatol 2009, 27:564-587.
46. Antony F.C., Sanclemente G., Calonje E., et al. Pigment synthesizing melanoma (so-called animal type melanoma): a clinicopathological study of 14 cases of a poorly known distinctive variant of melanoma. Histopathology 2006, 48:754-762.
47. Crowson A.N., Magro C.M., Mihm M.C. Malignant melanoma with prominent pigment synthesis: "animal type" melanoma-a clinical and histological study of six cases with a consideration of other melanocytic neoplasms with prominent pigment synthesis. Hum Pathol 1999, 30:543-550.
48. Diwan A.H., Lazar A.J. Nevoid melanoma. Clin Lab Med 2011, 31:243-253.
49. Zembowicz A., McCusker M., Calonje E., et al. Morphological analysis of nevoid melanoma: a study of 20 cases with a review of the literature. Am J Dermatopathol 2001, 23:167-175.
50. Schmoeckel C., Castro C.E., Braun-Falco O. Nevoid malignant melanoma. Arch Dermatol Res 1985, 277:362-369.
51. Kao G.F., Helwig E.B., Graham J.H. Balloon cell malignant melanoma of the skin. A clinicopathologic study of 34 cases with histochemical, immunohistochemical, and ultrastructural observations. Cancer 1992, 69:2942-2952.
52. Kosemehmetoglu K., Folpe A.L. Clear cell sarcoma of tendons and aponeuroses, and osteoclast-rich tumour of the gastrointestinal tract with features resembling clear cell sarcoma of soft parts: a review and update. J Clin Pathol 2010, 63:416-423.
53. Langezaal S.M., Graadt van Roggen J.F., Hogendoorn P.C., et al. Malignant melanoma is genetically distinct from clear cell sarcoma of tendons and aponeurosis (malignant melanoma of soft parts). Br J Cancer 2001, 84:535-538.
54. Panagopoulos I., Mertens F., Kardas I., et al. Molecular genetic characterization of the EWS/ATF1 fusion gene in clear cell sarcoma of tendons and aponeuroses. Int J Cancer 2002, 99:560-567.
55. Hisaoka M., Ishida T., Nishida K., et al. Clear cell sarcoma of soft tissue: a clinicopathologic, immunohistochemical, and molecular analysis of 33 cases. Am J Surg Pathol 2008, 32:452-460.
56. Wick M.R., Fitzgibbon J., Swanson P.E. Cutaneous sarcomas and sarcomatoid neoplasms of the skin. Semin Diagn Pathol 1993, 10(2):148-158.
57. Paradela S., Fonseca E., Prieto V.G. Melanoma in children. Arch Pathol Lab Med 2011, 135:307-316.
58. Paradela S., Fonseca E., Herzog C., et al. Prognostic factors for melanoma in children and adolescents: a clinicopathologic, single-center study of 137 Patients. Cancer 2010, 116:4334-4344.
59. Ruiz-Maldonado R., Orozco-Covarrubias M.L. Malignant melanoma in children. A review. Arch Dermatol 1997, 133:363-371.
60. Fishman C., Mihm M.C., Sober A.J. Diagnosis and management of nevi and cutaneous melanoma in infants and children. Clin Dermatol 2002, 20:44-50.
61. Livestro D.P., Kaine E.M., Muzikansky A., et al. Melanoma in the young: differences and similarities with adult melanoma: a case-matched controlled analysis. Cancer 2007, 110:614-624.
62. Gandini S., Sera F., Masini C., et al. Meta-analysis of risk factors for cutaneous melanoma: III. Family history, actinic damage and phenotypic factors. Eur J Cancer 2005, 41:2040-2059.
63. Tucker M.A. Melanoma epidemiology. Hematol Oncol Clin North Am 2009, 23:383-395.
64. Farmer E.R., Gonin R., Hanna M.P. Discordance in the histopathologic diagnosis of melanoma and melanocytic nevi between expert pathologists. Hum Pathol 1996, 27:528-531.
65. Corona R., Mele A., Piccardi P., et al. Interobserver variability on the histopathologic diagnosis of cutaneous melanoma and other pigmented skin lesions. J Clin Oncol 1996, 14:1218-1223.
66. Urso C., Rongioletti F., Chimenti S., et al. Interobserver reproducibility of histological features in cutaneous malignant melanoma. J Clin Pathol 2005, 58:1194-1198.
67. Cerroni L., Kerl H. Tutorial on melanocytic lesions. Am J Dermatopathol 2001, 23:237-241.
68. Shea C.R., Vollmer R.T., Prieto V.G. Correlating architectural disorder and cytologic atypia in Clark (dysplastic) melanocytic nevi. Hum Pathol 1999, 30:500-505.
69. Pozo L., Naase M., Diaz-Cano S.J., et al. Critical analysis of histologic criteria for grading atypical (dysplastic) melanocytic nevi. Am J Clin Pathol 2001, 115:194-204.
70. Shah K.N. The risk of melanoma and neurocutaneous melanosis associated with congenital melanocytic nevi. Semin Cutan Med Surg 2010, 29:159-164.
71. Duray P.H., Livolsi V.A. Recurrent dysplastic nevus following shave excision. J Dermatol Surg Oncol 1984, 10:811-815.
72. Ohsie S.J., Sarantopoulos G.P., Binder S.W., et al. Immunohistochemical characteristics of melanoma. J Cutan Pathol 2008, 35:433-444.
73. Cochran A.J., Wen D.R. S-100 protein as a marker for melanocytic and other tumours. Pathology 1985, 17:340-345.
74. Chorny J.A., Barr R.J. S100-positive spindle cells in scars: a diagnostic pitfall in the re-excision of desmoplastic melanoma. Am J Dermatopathol 2002, 24:309-312.
75. Kaufmann O., Koch S., Dietel M., et al. Tyrosinase, melan-A, and KBA62 as markers for the immunohistochemical identification of metastatic amelanotic melanomas on paraffin sections. Mod Pathol 1998, 11:740-746.
76. Ordonez N.G., Ji X.L., Hickey R.C. Comparison of HMB-45 monoclonal antibody and S-100 protein in the immunohistochemical diagnosis of melanoma. Am J Clin Pathol 1988, 90:385-390.
77. Trefzer U., Rietz N., Siegel P., et al. SM5-1: a new monoclonal antibody which is highly sensitive and specific for melanocytic lesions. Arch Dermatol Res 2000, 292:583-589.
78. Wick M.R., Swanson P.E., Rocamora A. Recognition of malignant melanoma by monoclonal antibody HMB-45. An immunohistochemical study of 200 paraffin-embedded cutaneous tumors. J Cutan Pathol 1988, 15:201-207.
79. Junkins-Hopkins J.M. Malignant melanoma: molecular cytogenetics and their implications in clinical medicine. J Am Acad Dermatol 2010, 63:329-332.
80. Kanitakis J., Narvaez D., Claudy A. Differential expression of the CD10 antigen (neutral endopeptidase) in primary versus metastatic malignant melanomas of the skin. Melanoma Res 2002, 12:241-244.
81. Curtin J.A., Fridlyand J., Kutzner H., et al. Distinct sets of genetic alterations in melanoma. N Engl J Med 2005, 353:2135-2147.
82. Pleasance E.D., Cheetham R.K., Greenman C.D., et al. A comprehensive catalogue of somatic mutations from a human cancer genome. Nature 2010, 463:191-196.
83. Blokx W.A., van Dijk M.C., Ruiter D.J. Molecular cytogenetics of cutaneous melanocytic lesions - diagnostic, prognostic and therapeutic aspects. Histopathology 2010, 56:121-132.
84. Smalley K.S. Understanding melanoma signaling networks as the basis for molecular targeted therapy. J Invest Dermatol 2010, 130:28-37.
85. van Dijk M.C., Bernsen M.R., Ruiter D.J. Analysis of mutations in B-RAF, N-RAS, and H-RAS genes in the differential diagnosis of Spitz nevus and spitzoid melanoma. Am J Surg Pathol 2005, 29:1145-1151.
86. Yazdi A.S., Palmedo G., Rutten A., et al. Mutations of the BRAF gene in benign and malignant melanocytic lesions. J Invest Dermatol 2003, 121:1160-1162.
87. Da Forno P.D., Pringle J.H., Potter L., et al. BRAF, NRAS and HRAS mutations in spitzoid tumours and their possible pathogenetic significance. Br J Dermatol 2009, 161:364-372.
88. Fullen D.R., Poynter J.N., Nair R.P., et al. BRAF and NRAS mutations in spitzoid melanocytic lesions. Mod Pathol 2006, 19:1324-1332.
89. Song J., Mooi W.J., Krausz T., et al. Nevus versus melanoma: to FISH, or not to FISH. Adv Anat Pathol 2011, 18:229-234.
90. Hornyak T.J. Future advances in melanoma research. Clin Plast Surg 2010, 37:169-176.
91. Bastian B.C., Olshen A.B., Pinkel D., et al. Classifying melanocytic tumors based on DNA copy number changes. Am J Pathol 2003, 163:1765-1770.
92. Bastian B.C., Xiong J., Busam K., et al. Genetic changes in neoplasms arising in congenital melanocytic nevi: differences between nodular proliferations and melanomas. Am J Pathol 2002, 161:1163-1169.
93. Gerami P., Zembowicz A. Update on fluorescence in situ hybridization in melanoma: state of the art. Arch Pathol Lab Med 2011, 135:830-837.
94. Gerami P., Jewell S.S., Ruffalo T., et al. Fluorescence in situ hybridization (FISH) as an ancillary diagnostic tool in the diagnosis of melanoma. Am J Surg Pathol 2009, 33:1146-1156.
95. Dalton S.R., Gerami P., LeBoit P.E., et al. Use of fluorescence in situ hybridization (FISH) to distinguish intranodal nevus from metastatic melanoma. Am J Surg Pathol 2010, 34:231-237.
96. Newman M.D., Mirzabeigi M., Gerami P. Chromosomal copy number changes supporting the classification of lentiginous junctional melanoma of the elderly as a subtype of melanoma. Mod Pathol 2009, 22:1258-1262.
97. Pouryazdanparast P., Newman M., Gerami P., et al. Distinguishing epithelioid blue nevus from blue nevus-like cutaneous melanoma metastasis using fluorescence in situ hybridization. Am J Surg Pathol 2009, 33:1396-1400.
98. Gerami P., Wass A., Busam K.J., et al. Fluorescence in situ hybridization for distinguishing nevoid melanomas from mitotically active nevi. Am J Surg Pathol 2009, 33:1783-1788.
99. Gaiser T., Kutzner H., Bruckner T., et al. Classifying ambiguous melanocytic lesions with FISH and correlation with clinical long-term follow up. Mod Pathol 2010, 23:413-419.
100. Smolle J., Soyer H.P., Kerl H. Proliferative activity of cutaneous melanocytic tumors defined by Ki-67 monoclonal antibody. A quantitative immunohistochemical study. Am J Dermatopathol 1989, 11:301-307.
101. Boni R., Doguoglu A., Dummer R., et al. MIB-1 immunoreactivity correlates with metastatic dissemination in primary thick cutaneous melanoma. J Am Acad Dermatol 1996, 35:416-418.
102. Rieger E., Hofmann-Wellenhof R., Smolle J., et al. Comparison of proliferative activity as assessed by proliferating cell nuclear antigen (PCNA) and Ki-67 monoclonal antibodies in melanocytic skin lesions. A quantitative immunohistochemical study. J Cutan Pathol 1993, 20:229-236.
103. Kanoko M., Ueda M., Ichihashi M. PCNA expression and nucleolar organizer regions in malignant melanoma and nevus cell nevus. Kobe J Med Sci 1994, 40:107-123.
104. Niemann T.H., Argenyi Z.B. Immunohistochemical study of Spitz nevi and malignant melanoma with use of antibody to proliferating cell nuclear antigen. Am J Dermatopathol 1993, 15:441-445.
105. Florenes V.A., Maelandsmo G.M., Holm R., et al. Cyclin A expression in superficial spreading malignant melanomas correlates with clinical outcome. J Pathol 2001, 195:530-536.
106. Tran T.A., Ross J.S., Mihm M.C., et al. Mitotic cyclins and cyclin-dependent kinases in melanocytic lesions. Hum Pathol 1998, 29:1085-1090.
107. Alonso S.R., Ortiz P., Acuna M.J., et al. Progression in cutaneous malignant melanoma is associated with distinct expression profiles: a tissue microarray-based study. Am J Pathol 2004, 164:193-203.
108. Florenes V.A., Faye R.S., Holm R., et al. Levels of cyclin D1 and D3 in malignant melanoma: deregulated cyclin D3 expression is associated with poor clinical outcome in superficial melanoma. Clin Cancer Res 2000, 6:3614-3620.
109. Balch C.M., Gershenwald J.E., Byrd D.R., et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009, 27:6199-6206.
110. Breslow A. Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg 1970, 172:902-908.
111. Barnhill R.L., Fine J.A., Berwick M., et al. Predicting five-year outcome for patients with cutaneous melanoma in a population-based study. Cancer 1996, 78:427-432.
112. Piris A., Mihm M.C., Duncan L.M. AJCC melanoma staging update: impact on dermatopathology practice and patient management. J Cutan Pathol 2011, 38:394-400.
113. Azzola M.F., Shaw H.M., Watson G.F., et al. Tumor mitotic rate is a more powerful prognostic indicator than ulceration in patients with primary cutaneous melanoma: an analysis of 3661 patients from a single center. Cancer 2003, 97:1488-1498.
114. Kesmodel S.B., Karakousis G.C., Wahl P.M., et al. Mitotic rate as a predictor of sentinel lymph node positivity in patients with thin melanomas. Ann Surg Oncol 2005, 12:449-458.
115. Litzner B, EE, Cockerell CJ. Tumor mitotic index in melanomas less than or equal to 1 mm in thickness: a Proscpective Study. Am J Dermatopathol, in press.
116. Balch C.M., Wilkerson J.A., Maddox W.A., et al. The prognostic significance of ulceration of cutaneous melanoma. Cancer 1980, 45:3012-3017.
117. Kanzler M.H., Swetter S.M. Malignant melanoma. J Am Acad Dermatol 2003, 48:780-783.
118. Piris A., Mihm M.C. Progress in melanoma histopathology and diagnosis. Hematol Oncol Clin North Am 2009, 23:467-480.
119. Googe P., King R., Page R., et al. Ulceration in thin melanoma. J Cut Pathol 2011, 38(1):112-113.
120. Clark W.H., From L., Mihm M.C., et al. The histogenesis and biologic behavior of primary human malignant melanomas of the skin. Cancer Res 1969, 29:705-727.
121. Maize J.C. Primary cutaneous malignant melanoma. J Am Acad Dermatol 1983, 8:857-863.
122. Zettersten E., Shaikh L., Kashani-Sabet M., et al. Prognostic factors in primary cutaneous melanoma. Surg Clin North Am 2003, 83:61-75.
123. Clark W.H., Elder D.E., Schultz D., et al. Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst 1989, 81:1893-1904.
124. Cipponi A., Wieers G., Coulie P.G., et al. Tumor-infiltrating lymphocytes: apparently good for melanoma patients. But why?. Cancer Immunol Immunother 2011, 60:1153-1160.
125. Burton A.L., Roach B.A., Vierling A.M., et al. Prognostic significance of tumor infiltrating lymphocytes in melanoma. Am Surg 2011, 77:188-192.
126. Blessing K., McLaren K.M. Histological regression in primary cutaneous melanoma: recognition, prevalence and significance. Histopathology 1992, 20:315-322.
127. Requena C., Botella-Estrada R., Guillen C., et al. Actas Dermosifiliogr 2009, 100:759-766. [in Spanish].
128. Olah J., Gyulai R., Dobozy A., et al. Tumour regression predicts higher risk of sentinel node involvement in thin cutaneous melanomas. Br J Dermatol 2003, 149:662-663.
129. Day C.L., Harrist T.J., Friedman R.J., et al. Malignant melanoma. Prognostic significance of "microscopic satellites" in the reticular dermis and subcutaneous fat. Ann Surg 1981, 194:108-112.
130. Harrist T.J., Rigel D.S., Rhodes A.R., et al. "Microscopic satellites" are more highly associated with regional lymph node metastases than is primary melanoma thickness. Cancer 1984, 53:2183-2187.
131. Leon P., Daly J.M., Synnestvedt M., et al. The prognostic implications of microscopic satellites in patients with clinical stage I melanoma. Arch Surg 1991, 126:1461-1468.
132. Rao U.N., Ibrahim J., Kirkwood J.M., et al. Implications of microscopic satellites of the primary and extracapsular lymph node spread in patients with high-risk melanoma: pathologic corollary of Eastern Cooperative Oncology Group Trial E1690. J Clin Oncol 2002, 20:2053-2057.
133. Shaikh L., Sagebiel R.W., Kashani-Sabet M., et al. The role of microsatellites as a prognostic factor in primary malignant melanoma. Arch Dermatol 2005, 141:739-742.
134. Nagore E., Oliver V., Fortea J.M., et al. Prognostic factors in localized invasive cutaneous melanoma: high value of mitotic rate, vascular invasion and microscopic satellitosis. Melanoma Res 2005, 15:169-177.
135. Cascinelli N., Santinami M., Pennacchioli E., et al. World Health Organization experience in the treatment of melanoma. Surg Clin North Am 2003, 83:405-416.
136. Cascinelli N., Morabito A., Belli F., et al. Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: a randomised trial. WHO Melanoma Programme. Lancet 1998, 351:793-796.
137. Cochran A.J., Wen D.R., Morton D.L. Management of the regional lymph nodes in patients with cutaneous malignant melanoma. World J Surg 1992, 16:214-221.
138. Ross M.I., Reintgen D., Balch C.M. Selective lymphadenectomy: emerging role for lymphatic mapping and sentinel node biopsy in the management of early stage melanoma. Semin Surg Oncol 1993, 9:219-223.
139. Reintgen D., Cruse C.W., Glass F., et al. The orderly progression of melanoma nodal metastases. Ann Surg 1994, 220:759-767.
140. Thompson J.F., McCarthy W.H., Paramaesvaran S., et al. Sentinel lymph node status as an indicator of the presence of metastatic melanoma in regional lymph nodes. Melanoma Res 1995, 5:255-260.
141. Gershenwald J.E., Ross M.I. Sentinel-lymph-node biopsy for cutaneous melanoma. N Engl J Med 2011, 364:1738-1745.
142. Scolyer R.A., Thompson J.F., Cochran A.J., et al. Intraoperative frozen-section evaluation can reduce accuracy of pathologic assessment of sentinel nodes in melanoma patients. J Am Coll Surg 2005, 201:821-823. [author reply: 823-4].
143. Gershenwald J.E., Thompson W., Tseng C.H., et al. Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol 1999, 17:976-983.
144. Statius Muller M.G., van Leeuwen P.A., Ferwerda C.C., et al. The sentinel lymph node status is an important factor for predicting clinical outcome in patients with Stage I or II cutaneous melanoma. Cancer 2001, 91:2401-2408.
145. Vuylsteke R.J., van Leeuwen P.A., Meijer S., et al. Clinical outcome of stage I/II melanoma patients after selective sentinel lymph node dissection: long-term follow-up results. J Clin Oncol 2003, 21:1057-1065.
146. Lowe J.B., Hurst E., Cornelius L.A., et al. Sentinel lymph node biopsy in patients with thin melanoma. Arch Dermatol 2003, 139:617-621.
147. Morton D.L., Thompson J.F., Essner R., et al. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med 2006, 355:1307-1317.
148. Morton D.L., Cochran A.J., Thompson J.F. The rationale for sentinel-node biopsy in primary melanoma. Nat Clin Pract Oncol 2008, 5:510-511.
149. Kanzler M.H., Levitt L., Lin A. Sentinel-node biopsy in melanoma. N Engl J Med 2007, 356:419. [author reply: 21].
150. Tejera-Vaquerizo A., Solis-Garcia E., Moreno-Ramirez D., et al. Actas Dermosifiliogr 2011, 102:255-263.
151. Dadras S.S., Lange-Asschenfeldt B., Muzikansky A., et al. Tumor lymphangiogenesis predicts melanoma metastasis to sentinel lymph nodes. Mod Pathol 2005, 18:1232-1242.
152. Drunkenmolle E., Marsch W., Helmbold P., et al. Paratumoral epidermal hyperplasia: a novel prognostic factor in thick primary melanoma of the skin?. Am J Dermatopathol 2005, 27:482-488.
153. Kashani-Sabet M., Sagebiel R.W., Miller J.R., et al. Vascular involvement in the prognosis of primary cutaneous melanoma. Arch Dermatol 2001, 137:1169-1173.
154. Straume O., Akslen L.A. Independent prognostic importance of vascular invasion in nodular melanomas. Cancer 1996, 78:1211-1219.
155. Quinn M.J., Crotty K.A., McCarthy W.H., et al. Desmoplastic and desmoplastic neurotropic melanoma: experience with 280 patients. Cancer 1998, 83:1128-1135.
156. Chen J.Y., Hruby G., Fitzgerald P., et al. Desmoplastic neurotropic melanoma: a clinicopathologic analysis of 128 cases. Cancer 2008, 113:2770-2778.
157. Larsen T.E., Grude T.H. A retrospective histological study of 669 cases of primary cutaneous malignant melanoma in clinical stage I. 3. The relation between the tumour-associated lymphocyte infiltration and age and sex, tumour cell type, pigmentation, cellular atypia, mitotic count, depth of invasion, ulceration, tumour type and prognosis. Acta Pathol Microbiol Scand A 1978, 86:523-530.
158. Schmoeckel C., Bockelbrink A., Braun-Falco O., et al. Low- and high-risk malignant melanoma-III. Prognostic significance of the resection margin. Eur J Cancer Clin Oncol 1983, 19:245-249.
159. Friedman R.J., Rigel D.S., Harris M.N., et al. Favorable prognosis for malignant melanomas associated with acquired melanocytic nevi. Arch Dermatol 1983, 119:455-462.
160. Masback A., Olsson H., Jonsson N., et al. Prognostic factors in invasive cutaneous malignant melanoma: a population-based study and review. Melanoma Res 2001, 11:435-445.
161. MacKie R.M., Aitchison T., Watt D.C., et al. Prognostic models for subgroups of melanoma patients from the Scottish Melanoma Group database 1979-86, and their subsequent validation. Br J Cancer 1995, 71:173-176.
162. Kaddu S., Smolle J., Kerl H., et al. Melanoma with benign melanocytic naevus components: reappraisal of clinicopathological features and prognosis. Melanoma Res 2002, 12:271-278.